Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Tool predicts response to platinum-based chemotherapy in ovarian cancer

A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of the National Cancer Institute.

16 Apr 2012

Ovarian cancer screening may not be needed on routine basis for all women says panel

In its latest review since 2004 of the benefits and harms of ovarian cancer screening, the United States Preventive Services Task Force found no new evidence to support routine screening.

12 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

Bimodal genes can define molecular subtypes of ovarian cancer

Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing.

9 Apr 2012

Gold nanostars can deliver drug directly to cancer cell nucleus

Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus -- an important feature for effective treatment.

6 Apr 2012

Uterine cancer up by 43% in UK over last two decades

Figures show that the number of diagnoses remained static for many years, but has increased by 43% since the 1990s. As the number of womb cancer cases have increased over the last decade, so have the number of womb cancer deaths. However, survival has also improved during that period, with 77% of women who are diagnosed with womb cancer now surviving for five years or more.

5 Apr 2012

Height and ovarian cancer link and diagnosis woes

A review of studies has revealed that taller women have a slightly higher risk of ovarian cancer. Obesity is also a risk factor among women who have never taken HRT, say international researchers. Previous studies have suggested a link, but there has been conflicting evidence.

4 Apr 2012

Study: Functional link between two major causes of treatment failure in breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows a functional link between two major causes of treatment failure in breast cancer, showing the protein behind one of these causes plays a role in increasing the drug resistance properties of the other.

4 Apr 2012

Genomic fortune-telling fails to provide informative guidance to most people

With sharp declines in the cost of whole genome sequencing, the day of accurately deciphering disease risk based on an individual's genome may seem at hand. But a study involving data of thousands of identical twins by Johns Hopkins investigators finds that genomic fortune-telling fails to provide informative guidance to most people about their risk for most common diseases, and warns against complacency born of negative genome test results.

3 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

Olaparib improves survival rates in platinum-sensitive relapsed serous ovarian cancer

Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."

28 Mar 2012

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.

27 Mar 2012

Vermillion fourth quarter total revenues increase 152% to $868,000

Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the fourth quarter and full year ended December 31, 2011.

From Quest Diagnostics 27 Mar 2012

Testosterone receptor may be a potential target for triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

26 Mar 2012

Testosterone may play a role in treatment of triple negative breast cancer

23 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin.

23 Mar 2012

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

19 Mar 2012

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Tool predicts response to platinum-based chemotherapy in ovarian cancer

Ovarian cancer screening may not be needed on routine basis for all women says panel

Soon a vaccine that targets 90% of all cancers

Bimodal genes can define molecular subtypes of ovarian cancer

Gold nanostars can deliver drug directly to cancer cell nucleus

Uterine cancer up by 43% in UK over last two decades

Height and ovarian cancer link and diagnosis woes

Study: Functional link between two major causes of treatment failure in breast cancer

Genomic fortune-telling fails to provide informative guidance to most people

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

Potential new therapy that kills cancer cells selectively

Olaparib improves survival rates in platinum-sensitive relapsed serous ovarian cancer

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

Vermillion fourth quarter total revenues increase 152% to $868,000

Testosterone receptor may be a potential target for triple negative breast cancer

Testosterone may play a role in treatment of triple negative breast cancer

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in